"Commercialization Guided Science Discovery and Critical Experiments" HSCI - iLab Series on Life Sciences Business Building


Tuesday, December 3, 2013, 6:00pm to 8:00pm


Harvard Innovation Lab, Batten Hall, 125 Western Ave., Boston, MA

This program is offered free to charge, but registration is required.  Please click here to register. 

Click here for a flyer to share with your lab.

Metered parking is available in lot adjacent to the iLab ('Hi').

In this workshop, Dr. Grayzel will use his own experience at Atlas Venture, Infinity Pharmaceutical, Arteaus Therapeutics, Annovation Biopharma, and other business building efforts to discuss early state venture creation and the process of translating scientific experiments within laboratories after initial scientific breakthrough, to create a persuasive dataset for fundraising and spinouts.  The speaker welcomes the audience to bring forward their own issues to be discussed by the speaker during the workshop to further illustrate the principles.

David Grayzel, Managing Director of Atlas Venture Development Corp (AVDC).  

AVDC is an innovative, asset centric structure that partners with pharma and biotech companies to develop late preclinical and clinical stage programs through to key value inflection points.  AVDC has created Arteaus Therapeutics and Annovation Biopharma.  Arteaus was funded by Atlas and Orbimed and is developing a CGRP antibody for migraine prevention. Annovation was funded by Atlas, Partners Innovation, and The Medicines Company and is developing novel anesthesia therapies.
Prior to joining Atlas in 2011, Dr. Grayzel led Infinity Pharmaceutical’s clinical research efforts as the head of clinical development and medical affairs. Having joined Infinity as a startup, Dr. Grayzel established the clinical capabilities to run trials from Phase I through global Phase III registration studies.  His responsibilities included clinical strategy and development, operations, pharmacovigilance, and medical affairs.  He also co-chaired the scientific leadership team.  In addition, as a member of the executive leadership team, he was instrumental in the overall corporate and business strategy, which included establishing corporate alliances with Medimmune/AZ and Purdue Pharma, as well as executing Infinity’s IPO in 2006.  Prior to Infinity, Dr. Grayzel was director of corporate development and business operations at Dyax, a biopharma company focused on antibody and protein therapeutics.

Dr. Grayzel received an MD from Harvard Medical School and completed his internship and residency training in internal medicine at Massachusetts General Hospital. Prior to his medical training, he was a curriculum director at Stanford University Medical Center, where he created Stanford’s first case-based medical ethics curriculum.  He received a BA with honors from Stanford University.

Dr. Grayzel serves on the board of Acera: The Massachusetts School for Science, Creativity, and Leadership, which he and his wife Courtney started in 2009. Most of his free time is spent with his children, Annabelle and Benjamin, sledding, swimming, and rooting for the NY Giants (but not the Yankees).

The HSCI - iLab Series:
To help promote translational research and commercialization of cutting edge scientific discoveries within Harvard and the broader life sciences community in the Boston area, Harvard Stem Cell Institute (HSCI) and Harvard Innovation Lab (iLab) are collaborating on a series of workshops since 2012.  These workshops focus on key issues faced by entrepreneurs and aim to provide broad perspectives as well as practical guidance.  The HSCI-iLab Series will also offer attendees an opportunity to learn about the translational and business building resources at HSCI and at iLab, as well as an opportunity to network with peers and industry veterans.

david_grayzel_december_3_2013.pdf133 KB